8th Jun 2020 17:12
(Alliance News) - Oxford Biomedica PLC on Monday said French pharmaceutical firm Sanofi SA plans to return the rights of two gene therapy programmes.
The Oxford-based cell therapy firm said Sanofi will return the rights to the SAR422459 and SAR421869 programmes.
SAR422459, Oxford Biomedica noted, is focused on treating Stargardt disease, which occurs in an area of the retina and can cause vision loss or impairment. SAR421869 is to treat Usher's syndrome, which could lead to partial or total hearing loss.
"This follows the group's announcement in February 2019 that Sanofi had informed Oxford Biomedica that it intended to seek a new partner for these two programmes which were originally partnered by the group to Sanofi back in 2009," Oxford Biomedica said.
"The timing of return of these programmes and operational details are yet to be determined. However, when the rights to the two programmes are returned, the group will undertake its own internal evaluation to determine the potential future for these programmes and decide whether to commit further resources to them."
Shares in the company closed 4.8% higher at 811.00 pence each in London on Monday.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica